Show simple item record

dc.contributor.authorD'Amico, Anthony V
dc.contributor.authorChen, Ming-Hui
dc.contributor.authorCrook, Juanita
dc.contributor.authorArmstrong, John G
dc.contributor.authorMalone, Shawn
dc.contributor.authorSteigler, Allison
dc.contributor.authorDunne, Mary
dc.contributor.authorKantoff, Philip W
dc.contributor.authorDenham, James W
dc.date.accessioned2012-05-08T11:08:38Z
dc.date.available2012-05-08T11:08:38Z
dc.date.issued2011-12-10
dc.identifier.citationDuration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. 2011, 29 (35):4682-7 J. Clin. Oncol.en_GB
dc.identifier.issn1527-7755
dc.identifier.pmid22042952
dc.identifier.doi10.1200/JCO.2011.37.0726
dc.identifier.urihttp://hdl.handle.net/10147/222411
dc.description.abstractWe evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subject.meshAged
dc.subject.meshAndrogen Antagonists
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshCohort Studies
dc.subject.meshCombined Modality Therapy
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshNeoplasm Staging
dc.subject.meshPrognosis
dc.subject.meshProstatic Neoplasms
dc.subject.meshTreatment Outcome
dc.titleDuration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.en_GB
dc.typeArticleen
dc.contributor.departmentBrigham and Women's Hospital, Boston, MA 02115, USA. adamico@partners.orgen_GB
dc.identifier.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.description.provinceLeinsteren
html.description.abstractWe evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories.


This item appears in the following Collection(s)

Show simple item record